Treatment options for a patient experiencing pruritic rash associated with transdermal testosterone: A review of the literature

Pharmacotherapy

Volumn 21, Issue 11, 2001, Pages 1425-1435

  McGriff, Nayahmka J ^a   Csako, Gyorgy ^a   Kabbani, Mahmoud ^b   Diep, Long ^c   Chrousos, George P ^b   Pucino, Frank ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTODERM TTS; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE;

ADULT; ARTICLE; CASE REPORT; DRUG DELIVERY SYSTEM; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; GEL; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; MALE; PRURITUS; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADULT; GELS; HORMONE REPLACEMENT THERAPY; HUMANS; INJECTIONS, INTRADERMAL; MALE; PRURITUS; TESTOSTERONE;

EID: 0035160713     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.17.1425.34428     Document Type: Article

References (62)

1. Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium
2. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders
3. The therapeutic use of androgens in women
4. Sex hormonal preparations and the liver
5. A review of contact dermatitis associated with transdermal therapeutic systems
6. Contact allergy to a testosterone patch
7. Allergic contact dermatitis from nitroglycerin contained in 2 transdermal systems
8. Clinical evaluation of the contact sensitization potential of a transdermal nicotine system
9. Allergic contact dermatitis from a clonidine transdermal delivery system
10. Delayed hypersensitivity to scopolamine delivered by a transdermal device
11. Allergic contact dermatitis from hydroxypropyl cellulose in a transdermal estradiol patch
12. Cutaneous irritancy
13. Androderm
14. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy
15. Pre-treatment with a topical corticosteroid cream improves local tolerability and does not significantly alter the pharmacokinetics of the Androderm® testosterone transdermal system in hypogonadal men
16. Skin pretreatment and the use of transdermal clonidine
17. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: A pilot study
18. Pharmacokinetics of a new testosterone formulation, COL-1621, for hormonal replacement in males
19. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men-a clinical research center study
20. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: Comparison to testosterone enanthate - A clinical research center study
21. Uses and abuses of the male sex hormone
22. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men
23. Testosterone replacement: When is there a role?
24. Emerging issues in androgen replacement therapy
25. Absorption of dihydrotestosterone (DHT) after its intramuscular administration
26. Initial trial of slow-release testosterone microspheres in hypogonadal men
27. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men
28. Testosterone buciclate (20 Aet-1) in hypogonadal men: Pharmacokinetics and pharmacodynamics of the new long-acting androgen ester
29. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men
30. Pharmacokinetics and pharmacodynamics of 7α-methyl-19-nortestosterone after intramuscular administration in healthy men
31. 7α-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men
32. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men - A clinical research center study
33. New androgen formulations
34. Pharmacokinetics of 7α-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men
35. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men
36. An analysis of testosterone implants for androgen replacement therapy Clin Endocrinol
37. Extrusion of testosterone pellets: A randomized controlled clinical study
38. The influence of implantation site on the extrusion rate and the pharmacokinetics of testosterone
39. Testoderm TTS, Testoderm
40. Allergy and topical irritation associated with transdermal testosterone administration: A comparison of scrotal and nonscrotal transdermal systems
41. Treatment of primary hypogonadism in men by the transdermal administration of testosterone
42. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone gel study group
43. Androgel
44. AACE clinical practice guidelines for the evaluation and treatment of hypogonadism in adult male patients
45. Free hormone measurements
46. A critical evaluation of simple methods for the estimation of free testosterone in serum
47. Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing
48. Testosterone and risk factors for cardiovascular disease in men
49. The pros and cons of testosterone replacement in elderly men: A panel discussion
50. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen
51. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III)
52. Chemistry
53. Hormonal regulation of serum lipoprotein(a) levels: Effects of parenteral administration of estrogen or testosterone in males
54. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis
55. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial
56. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
57. Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer
58. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
59. Androgens
60. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotropic hypogonadism